A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512689-32-00

Acronym

67856633LYM1002

Enrollment

Registered

2024-07-01

Start date

2021-07-15

Completion date

2025-02-13

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026